

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

MARINA DEL REY, Calif., Sept. 21, 2023 [/PRNewswire/](#) -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a panel discussion at the Cantor Global Healthcare Conference, which is being held in New York from September 26-28, 2023.

Armata's panel discussion is scheduled for Tuesday, September 26, from 2:45-3:15 PM ET.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Media Contacts:

At Armata:

Pierre Kyme

Armata Pharmaceuticals, Inc.

ir@armatapharma.com

310-665-2928

Investor Relations:

Joyce Allaire

LifeSci Advisors, LLC

jallaire@lifesciadvisors.com

212-915-2569

SOURCE Armata Pharmaceuticals, Inc.

<https://investor.armatapharma.com/2023-09-21-Armata-Pharmaceuticals-to-Participate-in-the-Cantor-Global-Healthcare-Conference>